FDA Approves Zytiga for High-Risk Prostate Cancer February 8, 2018 Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk castration-sensitive prostate cancer.Read more.Source: CURE Magazine Prostate Cancer News
Janssen Biotech announced that the Food and Drug Administration has approved Zytiga (abiraterone acetate) in combination with prednisone for high-risk castration-sensitive prostate cancer.Read more.Source: CURE Magazine
